Literature DB >> 3135811

Protection with phencyclidine against inactivation of 5-HT2 receptors by sulfhydryl-modifying reagents.

T Nabeshima1, K Ishikawa, K Yamaguchi, H Furukawa, T Kameyama.   

Abstract

We investigated whether phencyclidine (PCP)-induced head-twitch was antagonized in rats by ritanserin, a selective serotonin2 (5-HT2) receptor antagonist, to confirm the involvement of 5-HT neurons in PCP action and to discover whether PCP could protect the binding sites of [3H]PCP and [3H]ketanserin from the inhibitory effect of protein-modifying reagents which affect sulfhydryl groups. PCP (7.5, 10 and 12.5 mg/kg, i.p.)-induced head-twitch was completely antagonized by ritanserin (1 mg/kg, s.c.). Scatchard plots of specific [3H]PCP and [3H]ketanserin binding showed that sulfhydryl-modifying reagent, N-ethylmaleimide (NEM, 100 microM) caused a significant decrease in Bmax without changing Kd. PCP (10 microM) and ritanserin (1 microM) protected [3H]PCP and [3H]ketanserin binding sites from the decrease in the number induced by NEM (100 microM). 5-HT protected [3H]5-HT binding sites from inactivation by NEM, but PCP and ritanserin did not show any effect. On the basis of the present findings, it is concluded that PCP can interact with 5-HT2 receptors directly or allosterically, and 5-HT2 receptors may locate at PCP binding sites in membranes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3135811     DOI: 10.1016/0006-2952(88)90639-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Effect of psychotomimetics and some putative anxiolytics on stress-induced hyperthermia.

Authors:  A Lecci; F Borsini; L Gragnani; G Volterra; A Meli
Journal:  J Neural Transm Gen Sect       Date:  1991

2.  Hispidulin attenuates the social withdrawal in isolated disrupted-in-schizophrenia-1 mutant and chronic phencyclidine-treated mice.

Authors:  Akihiro Mouri; Hsin-Jung Lee; Takayoshi Mamiya; Yuki Aoyama; Yurie Matsumoto; Hisayoshi Kubota; Wei-Jan Huang; Lih-Chu Chiou; Toshitaka Nabeshima
Journal:  Br J Pharmacol       Date:  2020-04-03       Impact factor: 8.739

3.  Serotonergic/glutamatergic interactions: the effects of mGlu2/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli.

Authors:  J C Winter; J R Eckler; R A Rabin
Journal:  Psychopharmacology (Berl)       Date:  2003-11-04       Impact factor: 4.530

4.  A linear mixed-model approach to study multivariate gene-environment interactions.

Authors:  Rachel Moore; Francesco Paolo Casale; Marc Jan Bonder; Danilo Horta; Lude Franke; Inês Barroso; Oliver Stegle
Journal:  Nat Genet       Date:  2018-11-26       Impact factor: 38.330

5.  Hippocampal serotonin depletion unmasks differences in the hyperlocomotor effects of phencyclidine and MK-801: quantitative versus qualitative analyses.

Authors:  Wendy K Adams; Adam L Halberstadt; Maarten van den Buuse
Journal:  Front Pharmacol       Date:  2013-08-29       Impact factor: 5.810

6.  Genetic contributors to risk of schizophrenia in the presence of a 22q11.2 deletion.

Authors:  Isabelle Cleynen; Worrawat Engchuan; Matthew S Hestand; Tracy Heung; Aaron M Holleman; H Richard Johnston; Thomas Monfeuga; Donna M McDonald-McGinn; Raquel E Gur; Bernice E Morrow; Ann Swillen; Jacob A S Vorstman; Carrie E Bearden; Eva W C Chow; Marianne van den Bree; Beverly S Emanuel; Joris R Vermeesch; Stephen T Warren; Michael J Owen; Pankaj Chopra; David J Cutler; Richard Duncan; Alex V Kotlar; Jennifer G Mulle; Anna J Voss; Michael E Zwick; Alexander Diacou; Aaron Golden; Tingwei Guo; Jhih-Rong Lin; Tao Wang; Zhengdong Zhang; Yingjie Zhao; Christian Marshall; Daniele Merico; Andrea Jin; Brenna Lilley; Harold I Salmons; Oanh Tran; Peter Holmans; Antonio Pardinas; James T R Walters; Wolfram Demaerel; Erik Boot; Nancy J Butcher; Gregory A Costain; Chelsea Lowther; Rens Evers; Therese A M J van Amelsvoort; Esther van Duin; Claudia Vingerhoets; Jeroen Breckpot; Koen Devriendt; Elfi Vergaelen; Annick Vogels; T Blaine Crowley; Daniel E McGinn; Edward M Moss; Robert J Sharkus; Marta Unolt; Elaine H Zackai; Monica E Calkins; Robert S Gallagher; Ruben C Gur; Sunny X Tang; Rosemarie Fritsch; Claudia Ornstein; Gabriela M Repetto; Elemi Breetvelt; Sasja N Duijff; Ania Fiksinski; Hayley Moss; Maria Niarchou; Kieran C Murphy; Sarah E Prasad; Eileen M Daly; Maria Gudbrandsen; Clodagh M Murphy; Declan G Murphy; Antonio Buzzanca; Fabio Di Fabio; Maria C Digilio; Maria Pontillo; Bruno Marino; Stefano Vicari; Karlene Coleman; Joseph F Cubells; Opal Y Ousley; Miri Carmel; Doron Gothelf; Ehud Mekori-Domachevsky; Elena Michaelovsky; Ronnie Weinberger; Abraham Weizman; Leila Kushan; Maria Jalbrzikowski; Marco Armando; Stéphan Eliez; Corrado Sandini; Maude Schneider; Frédérique Sloan Béna; Kevin M Antshel; Wanda Fremont; Wendy R Kates; Raoul Belzeaux; Tiffany Busa; Nicole Philip; Linda E Campbell; Kathryn L McCabe; Stephen R Hooper; Kelly Schoch; Vandana Shashi; Tony J Simon; Flora Tassone; Celso Arango; David Fraguas; Sixto García-Miñaúr; Jaume Morey-Canyelles; Jordi Rosell; Damià H Suñer; Jasna Raventos-Simic; Michael P Epstein; Nigel M Williams; Anne S Bassett
Journal:  Mol Psychiatry       Date:  2020-02-03       Impact factor: 15.992

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.